It also sells quite a bit of a series of much needed vaccines. So it generates very significant revenue. Little by little -- despite Tangerine 2.0 nonsense, the stock analysts and the market broadly, are beginning to appropriately value this fine company. [To be fair, I still believe it should be trading around $80 a share, and it is a little under half of that right now.] Here's the latest:
. . .Moderna jumped 7.8% in the afternoon session after the stock's positive momentum continued as the Coalition for Epidemic Preparedness Innovations (CEPI) announced it would invest up to $54.3 million to support a pivotal Phase 3 clinical trial for the company's investigational mRNA-based pandemic influenza vaccine candidate, mRNA-1018.
This late-stage study would be the first of its kind for an mRNA-based vaccine targeting pandemic influenza, aiming to advance the candidate toward licensure. The funding was seen as a significant step forward for the program, which had faced uncertainty. Earlier in the year, the U.S. government had cut federal funding for the vaccine candidate. The fresh capital from the global partnership provides a new opportunity for Moderna's bird flu vaccine, allowing the company to proceed with the crucial final stage of testing before potential approval. . . .
Now you know. . . onward, grinning -- 80° here as a high today.
नमस्ते
No comments:
Post a Comment